Tender Offer - Inozyme Pharma, Inc.

Form Type: SC14D9C

Filing Date: 2025-05-16

Corporate Action: Tender-offer

Type: New

Accession Number: 000119312525121735

Filing Summary: Inozyme Pharma, Inc. has filed a Schedule 14D-9 regarding a planned cash tender offer by Incline Merger Sub Inc., a wholly owned subsidiary of BioMarin Pharmaceutical Inc. The tender offer aims to acquire all outstanding shares of Inozyme common stock at a specified price once commenced. This transaction is the result of a Merger Agreement dated March 16, 2025, with the merger designating Inozyme as the surviving corporation under Delaware law. The filing serves as preliminary communication related to the tender offer and provides insights into the strategic rationale behind the acquisition, highlighting potential benefits for BioMarin’s enzyme therapy portfolio and details regarding Inozyme’s product candidate, INZ-701, aimed at treating ENPP1 Deficiency. The forward-looking statements indicate expected benefits, market potential, and anticipated timelines related to the development and regulatory approval of INZ-701. Stakeholders are advised to be cognizant of the risks and uncertainties associated with the acquisition and advised to read all relevant tender offer documents as they become available.